Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Follow-Up Questions
Edwards Lifesciences Corp (EW) の株価収益率はいくらですか？
Edwards Lifesciences Corp の株価収益率は 10.2524 です。
Edwards Lifesciences Corp のCEOは誰ですか？
Mr. Bernard Zovighian は Edwards Lifesciences Corp の Chief Executive Officer で、2016 から在籍しています。
EW の株価パフォーマンスは？
EW の現在の価格は $84.15 で、最終取引日から 0% decreased 変動しました。
Edwards Lifesciences Corp の主な事業テーマや業界は？
Edwards Lifesciences Corp は Health Care 業界、セクターは Health Care に属しています。
